HISUN(SH:600267)2017-10-30 16:00Financial Performance - Operating revenue for the first nine months was ¥8.18 billion, representing an increase of 11.46% year-on-year[7]. - The net profit attributable to shareholders of the listed company was -¥17.70 million, an improvement of 85.97% compared to -¥126.19 million in the previous year[8]. - Basic earnings per share decreased by 84.38% to ¥0.005 from ¥0.032 in the same period last year[8]. - The company reported a net profit of ¥303,766,262.77 for the first nine months, compared to ¥132,217,074.91 in the previous year, marking a significant increase[34]. - Operating profit for the third quarter was ¥79,883,359.50, compared to a loss of ¥7,363,050.35 in the same period last year[34]. - The company reported a net loss attributable to shareholders of approximately ¥8.39 million in Q3 2017, compared to a profit of ¥10.66 million in the same period last year[37]. - Operating profit for the first nine months of 2017 was approximately -¥15.24 million, an improvement from -¥69.29 million in the same period of 2016[37]. - The total comprehensive income for Q3 2017 was approximately ¥42.01 million, compared to ¥71.74 million in Q3 2016, a decrease of 41.6%[36]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥21.91 billion, an increase of 5.55% compared to the end of the previous year[7]. - The company’s total liabilities decreased by 43.62% to RMB 460,615,825.00, primarily due to repayment of long-term borrowings[15]. - The company's total liabilities reached RMB 13,737.77 million, up from RMB 12,719.04 million at the start of the year[28]. - The company's total equity as of September 30, 2017, was RMB 8,172.10 million, compared to RMB 8,039.23 million at the beginning of the year[28]. - Total liabilities rose to ¥5,329,369,649.38 from ¥5,144,116,353.11, representing an increase of approximately 3.61%[31]. Cash Flow - Net cash flow from operating activities for the first nine months was ¥642.78 million, up 41.08% from the same period last year[7]. - Cash inflow from operating activities for the first nine months of 2017 was 8,143,980,837.43 CNY, slightly down from 8,185,729,295.04 CNY year-over-year[40]. - The net cash flow from operating activities increased to 642,782,520.97 CNY from 455,626,549.72 CNY in the previous year[41]. - Cash outflow for investing activities totaled 1,639,230,647.91 CNY, compared to 2,032,817,746.50 CNY in the same period last year, resulting in a net cash flow of -980,356,893.59 CNY[41]. - Cash inflow from financing activities was 6,070,973,668.36 CNY, up from 5,237,101,876.85 CNY year-over-year[41]. Shareholder Information - The total number of shareholders at the end of the reporting period was 29,905[12]. - The largest shareholder, Zhejiang Haizheng Group Co., Ltd., held 33.22% of the shares[12]. Investments and Developments - The company plans to establish Zhejiang Haikun Pharmaceutical Co., Ltd. with a cash investment of RMB 10 million, holding 100% equity[17]. - The company approved a capital increase for Haizheng Biopharmaceutical Co., Ltd. with an asset valuation of RMB 327.68 million, aiming to specialize in monoclonal antibody operations[18]. - The company holds 39% and 61% stakes in Haizheng Biopharmaceutical with a total investment value of approximately RMB 15,453.87 million and RMB 27,060.05 million respectively for the establishment of a specialized diabetes subsidiary[19]. - The company plans to invest RMB 510 million to establish Zhejiang Haizheng Investment Management Co., holding a 51% stake in the company with a registered capital of RMB 1,000 million[20]. - The company is in the process of transferring a 21.05% stake in IMD Natural Solutions GmbH to Lanxess AG, with the transfer proceeding as planned[21]. Other Financial Metrics - Prepayments increased by 114.61% to RMB 285,417,463.87 due to increased advance payments for third-party business by a wholly-owned subsidiary[15]. - Development expenditures rose by 42.05% to RMB 920,659,817.48, reflecting increased R&D investments during the development phase[15]. - Other receivables increased by 41.53% to RMB 48,469,745.93, primarily due to increased temporary loans from subsidiary business activities[15]. - The company reported a 79.42% decrease in investment income to RMB 15,666,458.51, mainly due to reduced gains from equity disposals[15]. - Other income increased to RMB 34,311,549.34, attributed to changes in government subsidy reporting[15]. Audit and Reporting - The report has not been audited, which may affect the reliability of the financial data presented[5]. - The company has not disclosed any new product developments or market expansion strategies in this report[6].